Book a Free Consultation with our Health Advocates
Stem cell therapy for chronic pain may provide an answer for people suffering from persistent discomfort, such as arthritis, who believe there is no cure. Pain medication can have unpleasant side effects such as sleepiness, constipation, stomach or liver damage, and addiction; this is not a long-term solution for those suffering from chronic pain. They are only a band-aid solution. Pain management in the 21st century should be more effective. Stem cell treatment for chronic pain has been universally successful, but many people are still not sufficiently aware of what it is and how it works to give it a chance. Here’s what you should know.
Chronic pain is unquestionably a widespread problem. The Centers for Disease Control and Prevention (CDC) reported in 2018 that an estimated 50 million Americans, or slightly more than 20 per cent, suffer from chronic pain. This figure is steadily increasing.
When stem cells are implanted, they cause a beneficial inflammation that allows the ligaments and tendons inside our joints to begin to mend and renew. It is critical to recognize that inflammation is not a side effect; rather, it is the desired goal.
A certain degree of inflammation around an injury is a sign of healing; consider how your body forms a scab over a scratch or cut. That is your body causing inflammation in order to heal. Stem cell therapy for chronic back pain, and discomfort in other parts of the body, is very similar.
Pain is a symptom, not an illness or a condition. It is the body’s method of indicating that there is a problem that has to be addressed as a result of an accident or age-related degeneration. Stem cell treatment can effectively address the underlying illness while also providing relief from the persistent pain.
Here are some common examples:
Currently, stem cell therapy for chronic pain is seen as most successful in treating discomfort in specific parts of the body, since stem cells are so adept at repairing damaged ligaments and tendons, creating better and stronger joints. Some of these are:
Stemwell uses cord tissue-derived mesenchymal stem cells ethically sourced from full-term human umbilical cords (We do not utilize cells from embryos). We then administer more than 300 million cells that are all thoroughly tested for viability before treatment. These cells are NOT a blood product; therefore, it is extremely safe and does not require HLA or phenotypic matching.
Video call with our patient advocates and our doctors where the patient’s condition and medical history will be discussed.
The patient undergoes an initial evaluation and blood work by Stemwell’s doctor.
Endovenous detox therapy applied to patient
Stem Cell IV Infusion Therapy + localized Autologous stem cell injections in trigger pain points
Hyperbaric Chamber therapy – Hyperbaric oxygen reduces inflammation, oxygenates injured muscle, and regenerates skeletal muscle via macrophage and satellite cell activation.
The fifth step is dedicated to addressing chronic pain with specialized therapies, which encompass shockwave therapy, ultrasound, magnetotherapy, and laser therapy. In specific instances, we may also incorporate photobiomodulation to address chronic pain or explore its potential benefits
*Each Protocol is customized to the patient depending their medical and surgical history
This protocol information is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, is for general information purposes only.
Orthobiologics are biological substances that are typically connected with sports and traction injuries, such as platelet-rich plasma (PRP) or stem cells. These are used to accelerate the healing of musculoskeletal injuries. They can be used alone or in conjunction with traditional pharmaceutical and non-pharmaceutical therapy options. Orthobiologic therapies, in particular, deliver high concentrations of naturally occurring cellular concentrates to an injury with the goal of accelerating the regeneration of muscles, ligaments, tendons, and bones, hence reducing recovery time and injury-related inflammation and discomfort.
Orthobiologic therapies are utilized in sports medicine to treat both acute and chronic disorders, including typical overuse injuries. Athletes and orthopedists frequently turn to orthobiologic therapy with the aim of quickly restoring an athlete to pre-injury physical condition. Generally, orthopedists will use biologics instead of medicines and/or invasive surgery.
The science of regenerative medicine has seen great growth, particularly in the field of orthopedic surgery. Mesenchymal stem cells (MSCs) offer great regenerative potential, aiming to slow or halt chronic illness while also improving function and patient quality of life. Autologous bone marrow concentrate (BMC), adipose tissue, and allogenic umbilical cord-derived Wharton’s jelly (UC-WJ) can all be used to generate MSCs. These biologic techniques are becoming increasingly widespread in orthopedic treatment, owing to increased patient awareness and recent breakthroughs in MSC therapy.
In comparison to other sources, BMC and adipose-derived stem cells (ADSCs) are therapeutically available and have a lengthy history of use with good clinical results. However, both stem cell sources have drawbacks. BMC is linked to surgical site morbidity from the aspiration operation, a low quantity of MSCs in the aspirated bone marrow concentration, and early senescence. Although adipose-derived stem cells promise short-term clinical benefits, research on this topic is restricted, with few randomized controlled studies and insufficient long-term follow-up. Adipose-derived stem cells are also linked to donor site morbidity as a result of the extraction procedure.
WJ is an allogenic tissue made up of connective tissue in the umbilical cord. It withstands torsional and compressive pressures imposed on the umbilical arteries during fetal development. The UC-WJ contains primitive MSCs. These perinatal MSCs resemble embryonic stem cells (ESCs) yet have many of the characteristics of adult MSCs. When compared to other tissue types, Wharton’s jelly has the highest concentration of MSCs/mL. UC-derived Wharton’s jelly also contains a high concentration of extracellular matrix (ECM) components like collagen, hyaluronic acid, chondroitin sulfate, and sulfated proteoglycans.
In comparison to autogenic tissues, Wharton’s jelly is more freely accessible and available. The UC, and the Wharton’s jelly contained inside it, is an after-birth tissue that is often eliminated after each birth. This ease of collection has various advantages over the current BMSC and ADSC harvests, both of which can cause donor site morbidity. This characteristic, together with the multipotency of Wharton’s jelly stem cells (WJSCs), makes Wharton’s jelly an excellent source of MSCs for regenerative medicine applications in orthopedic surgery.
Our mission is to bring hope, healing, and a personalized plan to every patient we meet. We believe the caring hands and expertise of our doctors along with our proven protocols provide the best possible outcomes. We follow the highest ethical international standards offering transparency, honesty, and clinical accuracy.
AddressCra. 13 #118-08, Bogotá, Colombia
Stem cell therapy offers no guarantees and is not promoted as a cure. This is similar to many other medical treatments. Reviewing the patient’s medical history is necessary to determine stem cell therapy eligibility. Any personal information provided is for internal and medical use with our medical providers only. The Stemwell Health headquarters is located in McLean, Virginia. Stemwell Health Virginia is not a stem cell treatment facility or surgical center. Treatments are not conducted anywhere in the US, since these advanced therapies are not yet FDA-approved. All cell therapies are conducted in Colombia where it is regulated by the ministry of health, INVIMA (Columbia’s FDA equivalent) and other local authorities. All treatments are performed within the country’s legal limits and regulatory framework where the specific medical provider practices.